Lebsanan

Tacrolimus, the active ingredient in Lebsanan, is a calcineurin inhibitor presented as a topical formulation for skin application. It is used to manage inflammatory skin conditions such as atopic dermatitis and eczema in patients requiring localized immunosuppression.

GNH USA supplies Lebsanan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lebsanan (tacrolimus) is a topical calcineurin inhibitor used to treat inflammatory skin disorders. - Atopic dermatitis: reduces inflammation and pruritus, improving skin barrier function. - Eczema: alleviates redness, itching and scaling associated with chronic eczema. - Pruritic inflammatory skin disorders: provides relief from persistent itching and inflammation when conventional therapies are insufficient.

Topical tacrolimus may cause local and systemic adverse reactions.

Common Side Effects: - Burning sensation at the application site. - Itching or pruritus. - Redness or erythema. - Skin irritation or dryness. - Stinging feeling. - Mild acneiform eruptions.

Serious or Rare Side Effects: - Secondary skin infection. - Allergic contact dermatitis. - Systemic immunosuppression leading to increased infection risk. - Possible malignancy risk with long‑term use. - Lymphadenopathy or unexplained fever.

Use Lebsanan only under medical supervision and follow prescribed instructions. - Avoid application on infected or broken skin: may worsen infection. - Do not use on extensive body surface areas without guidance: limits systemic absorption. - Monitor for signs of infection or unusual skin changes: report promptly. - Limit sun exposure and use sunscreen: tacrolimus may increase photosensitivity. - Store at room temperature: keep in original container, protect from moisture and light.

Tacrolimus topical can interact with other agents that affect immune function or skin absorption.

Major Interactions (Avoid): - Systemic immunosuppressants (e.g., cyclosporine, azathioprine): additive immunosuppression. - Live vaccines: risk of reduced vaccine efficacy. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic tacrolimus levels.

Moderate Interactions (Monitor Closely): - Topical antibiotics: monitor for irritation. - Other topical steroids: assess cumulative immunosuppressive effect. - Phototherapy: observe for enhanced photosensitivity.